Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, sometimes via third party companies, which offer retrospective financial rebates to Greater Manchester Integrated Care Board (GMICB) based on primary care prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or the GMMMG formulary.
All rebate applications are assessed against the GMMMG Ethical Framework for Primary Care Rebate schemes, which can be found at the bottom of this page along with the application form.
Please direct any enquiries regarding primary care rebate schemes to firstname.lastname@example.org.
The primary care rebate schemes to which GMICB has signed up are as follows:
|Company||Product||Start date||End date|
|Chiesi Ltd||Fostair NEXTHaler dpi||01/10/2022||30/09/2023|
|Chiesi Ltd||Fostair pMDI||01/10/2022||30/09/2023|
|Ferring Pharmaceuticals Ltd||Firmagon||01/07/2022||31/12/2024|
|Merck Serono Ltd||Glucophage SR||01/07/2022||30/06/2023|
|Sandoz Ltd||AirFluSal Forspiro||01/07/2022||30/03/2023|
|Viatris UK Healthcare Ltd||Sirdupla||01/07/2022||31/03/2023|
|Document Title||Issue Date||Review Date||Status|
|Ethical Framework for Primary Care Rebate Applications||20220903 Sep 2022||Version 9.1|
|Primary Care Rebate Scheme Application form||20220903 Sep 2022||Version 5.1|